Gain Therapeutics Inc
NASDAQ:GANX
| Market Cap (Intraday) | 51.58M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.28 |
| 50-Day MA | $4.15 |
| 200-Day MA | $3.54 |
Gain Therapeutics Inc Stock, NASDAQ:GANX
4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814
United States of America
Phone: +1.301.500.1556
Number of Employees: 32
Description
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.